slide1 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Wendy R. Sanhai, Ph.D., M.B.A. Senior Scientific Advisor Office of Chief Scientist PowerPoint Presentation
Download Presentation
Wendy R. Sanhai, Ph.D., M.B.A. Senior Scientific Advisor Office of Chief Scientist

Loading in 2 Seconds...

play fullscreen
1 / 28

Wendy R. Sanhai, Ph.D., M.B.A. Senior Scientific Advisor Office of Chief Scientist - PowerPoint PPT Presentation


  • 131 Views
  • Uploaded on

ANALGESIC CLINICAL TRIAL INNOVATIONS, OPPORTUNITIES, AND NETWORKS (ACTION) ACTION Inaugural Workshop 6-15-11. Evolution of the ACTION Initiative and Public Private Partnerships in the Context of FDA’s Public Health Mission and Regulatory Science. Wendy R. Sanhai, Ph.D., M.B.A.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Wendy R. Sanhai, Ph.D., M.B.A. Senior Scientific Advisor Office of Chief Scientist' - iona


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

ANALGESIC CLINICAL TRIAL INNOVATIONS, OPPORTUNITIES, AND NETWORKS (ACTION)ACTION Inaugural Workshop 6-15-11

slide2

Evolution of the ACTION Initiative and Public Private Partnerships in the Context of FDA’s Public Health Mission and Regulatory Science

Wendy R. Sanhai, Ph.D., M.B.A.

Senior Scientific Advisor

Office of Chief Scientist

Office of the Commissioner, FDA

2

fda s mission statement
FDA’s Mission Statement
  • “The FDA is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation.
  • The FDA is also responsible for advancing the public health by helping to speed innovations that make medicines and foods more effective, safer, and more affordable; and helping the public get the accurate,science-basedinformation they need to use medicines and foods to improve their health.”
public health context unmet need
Public Health Context: “Unmet Need”
  • The most widely used analgesics are opioids, NSAIDs and acetaminophen
    • All have serious toxicities, even when used properly
  • Development of novel analgesic products has been slow and challenging
    • Clinical trials frequently fail to show efficacy
    • Pharmaceutical industry is reluctant to take on the risk of developing of novel analgesics due to hurdle of achieving successful outcomes in expensive clinical trials
current state of affairs
Current State of Affairs
  • Clinical studies, particularly efficacy trials, notoriously flawed for analgesic drug development
    • Frequent studies failures with drugs known to be effective
    • Extremely small treatment effects even when successful
    • Multiple causes, e.g.:
      • Large placebo effect
      • Missing data
      • Study design flaws
      • Study analysis flaws
      • Investigator quality
      • Frequent use of foreign sites
overall action objectives
Overall ACTION Objectives
  • To conduct critical research, including analysis of existing data to:
    • improve the success rates of analgesic trials and guide the design of future trials
    • facilitate efficient development of safer and more effective analgesic drug products
why public private partnerships
Why Public Private Partnerships?
  • Any single party: limited resources (staff, funds, infrastructure, equipment…), time and expertise
    • Leverage resources and expertise among stakeholders to minimize costs (time and money)
    • Align missions toward mutually beneficial goals
    • Open new lines of communication among partners
    • Create value added for all stakeholders: optimizing economies of scale…advancing public health
  • Whole = Greater than sum of individual parts/partners
it will take a village
…It will take a village
  • Pain researchers and clinicians(academia, other research institutions)
  • Professional organizations
  • Government agencies
  • Pharmaceutical and device companies
  • Patients and patient advocacy organizations
  • Non-profit foundations
building the foundation for action prior to action ppp launch all funding from cder
Building the Foundation for ACTION(prior to ACTION PPP launch; All funding from CDER)
  • Three initial projects
    • 1 data reanalysis project
    • 1 clinical protocol development project
    • 1 data transformation/standardization project
  • Partners
    • Univ. Pennsylvania
    • SAS Institute/Executive Information Services (EIS)
  • Funding:
    • FY ’07: $50K; FY ’08: $250K; FY ’09: $500K
action timeline
ACTION Timeline

First ACTION Discussions (FDA)

ACTP Workshop (Ashburn)

ACTION Contract Solicitation

ACTION Manuscript published

ACTION Inaugural Workshop

ACTION/

IMMPACT Discussions

FDA-internal ACTION contract process begun

ACTION Contract to U Rochester

ACTION Cooperative Agreement RFP

2010 action contract
2010 ACTION Contract
  • Issued in September 2010, under the Critical Path Initiative
  • Aggressive 1-year timeline
  • Goals:
    • Establish ACTION PPP: robust foundation for future activities
      • Governance board
      • Operating principles
      • Scientific oversight committee
    • Perform analysis of selected pain trial data
    • Conduct scientific workshop (June 15, 2011)
ppp operating principles
PPP Operating Principles
  • Transparency: maintain public trust
  • Inclusion of interested/affected stakeholders
    • FDA, industry, academia, professional societies, patient advocates, NIH, other gov’t, …
  • Leveraging resources
    • Existing and prospective data
    • Claims data
    • Personnel & scientific expertise
    • Project funding
  • Focused on public health and efficient product development
  • Mutually beneficial to partners
action ppp governance structure
ACTION PPP Governance Structure

Executive Committee (EC)

Board of Advisors

(BOA)

Scientific and Professional

Advisory and

Recommendations

Committee (SPARC)

ACTION Coordinating

Center /

Steering Committee

Working Groups (WGs):

EC and SPARC approved

projects and activities

basic steps in collaborating with fda not comprehensive not consecutive

Identify gaps/opportunities

(avoid duplication)

  • Identify partners: define roles/responsibilities
  • Co-develop: proposals, budgets, timelines etc.
  • Leverage resources/expertise
  • Implement joint Proof of Concept projects
  • Share data in public domain as quickly as appropriate: Pre & Pro-competitive tools

Some Benefits

PRIVATE PARTNERS: Regulatory Knowledge, Predictive Tools & Input in Project Selection

FDA: Guidances, Standard-setting, Evaluative Tools

PAITENTS: Faster, Safer and Cheaper Medical Products!!!!

Basic Steps in Collaborating with FDA (not comprehensive! not consecutive!)

Start with the Public Health Need, SCIENCE!

Identify Priorities for multiple stakeholders

elements of a ppp
Elements of a PPP

SCIENCE

PPP

BUSINESS

  • Develop business plan/strategy
  • Create governance/Adm Oversight
  • Identify & recruit partners
  • Negotiate agreements, IP etc
  • Administer/manage contracts
  • Manage conflicts of interest
  • Develop data sharing guidelines
  • Develop reports/output analysis
  • Develop protocols, timelines
  • Determine public health questions
  • Obtain stakeholder input
  • Identify other efforts: join, expand
  • Coauthor scientific articles
  • Interpret scientific data
some elements of business model
Some Elements of Business Model
  • Pooling: IP, resources, expertise…
  • Share Data: Proprietary, Pre-clinical, clinical, pro-competitive?
  • Models: Sematech, SNP & Biomarker Consortia, C-Path Institute
  • Contracts/Agreements with timelines, deliverables, specific terms and conditions? (Licenses: non-exclusive commercial, research-use?)
  • Implement POC project/s
  • Develop: Research/predictive tools, know-how, guidances
  • Employ multiple mechanisms

Data/Deliverables FDA Guidances R&D, CMS, Clinical Decisions

action plan
ACTION Plan
  • RFI issued on 12/18/09
  • Responses reviewed and elements incorporated into ACTION RFP
  • ACTION Initiative RFP issued on 7/22/10
  • Elements of the RFP….
action rfp
ACTION RFP

Develop Strategic Plan in order to:

  • Identify and establish relationships with key experts in the field
  • Create an Executive Committee with representation from key stakeholders
  • Establish an independent scientific oversight body to coordinate the overall scientific mission of the ACTION Initiative
  • Develop methodologies for the transformation of pooled trial data from multiple analgesic trials
general funding model
General Funding Model

Whole is greater than sum of parts/partners

Public

Private Only

Private

Public Only

Individually or

in groups

launch project/s

Launch PPPs with combination

of public/private funds

with mutually beneficial

goals and objectives

FDA, NIH, CMS

Other government

Data, new guidances, best practices, informed clinical decisions, evidence based medicine

Effective & safe medical products to patients faster, and more efficiently

potential sources of funding

State Funds

Grants

Appropriations

Other…

Private Funders

Potential Sources of Funding

ACTION

Project 1

Project 3

Project 2

slide22

ACTION Executive Committee Co-Chairs

  • American Academy of Neurology
  • American Academy of Pain Medicine
  • American College of Rheumatology
  • American Pain Society
  • American Society of Anesthesiologists
  • Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT)
  • International Association for the Study of Pain
  • Outcome Measures in Rheumatology (OMERACT)
  • ACTION liaisons:
    • EuroPain
    • German Neuropathic Pain Research Network
slide23

Partners

Agreements

Partnership

Projects

Public Health Need

slide24

ACTION ongoing activities

  • Methodologically-focused meta-analyses of publicly-available randomized clinical trials
    • e.g., neuropathic pain, osteoarthritis
  • Methodologically-focused retrospective analyses of patient-level raw data provided by FDA and by industry
  • STandardized ANalgesic DAtabase for Research, Discovery, and Submissions (STANDARDS)
    • development of CDISC-compliant database format for retrospective pooling and prospective use
  • Request for Information Draft Strategic Plan Request for Proposals
  • Scientific Workshop at FDA White Oak facility (6/15/11)
    • identify obstacles and finalize Strategic Plan
slide25

FUTURE “ACTIONS”

  • Research
    • Facilitate collaborations among stakeholders
    • Sponsor analyses of pooled legacy data
    • Develop more efficient clinical trial designs
    • Reduce patient burden and study costs
    • Explore biomarkers and patient phenotyping
2011 fda strategic priorities
2011 FDA Strategic Priorities
  • Transforming development of medical countermeasures against threats to US and global health and security
  • Innovation in product development and evaluation: biomarkers, personalized medicine and effective clinical studies
  • Harnessing diverse data through information science to improve public health
  • Modernizing toxicology and risk assessment to better predict safety
  • Supporting new approaches to improve product manufacturing and quality
  • Protecting the food supply
  • Assuring FDA’s readiness to evaluate new and emerging technologies
  • Advancing behavioral science to empower informed decision making and use of products by professionals and consumers